- May 21, 2025Be sure to catch up on the latest happenings in our fall newsletter here!
- May 21, 2025Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three…
- May 21, 2025Below is a resource for our patients: Taylor & Francis is a publisher of peer-reviewed medical journals. We publish a…
- May 14, 2025- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk…
- April 3, 2025PALO ALTO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new…
- March 26, 2025CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
- March 21, 2025− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency…
- February 26, 2025An Unexpected Benefit of Adding the Patient Voice to Medical Education—Train Providers to Be Better Mackenzie N. Boedicker, MS, BS…
- February 26, 2025Mystery Solved: New Research Reveals Why a Key Protein Turns Deadly in Aging Bodies By Scripps Research Institute January 30,…
- February 20, 2025"Light the Night for Amyloidosis" is an awareness campaign designed to raise awareness about the symptoms, diagnosis, treatment, and potential…
7151 N. Main St. Ste. 2 Clarkston, MI 48346
248-922-9610